Lundbeck Inc. Announces the Voluntary Nationwide Recall of Two Lots of NeoProfen® (ibuprofen lysine) Injection Recall will Result in Temporary Product Shortage

["U.S. Food & Drug Administration (FDA)" <fda@xxxxxxxxxxxxxxxxxxxxxxx>]

Title: Lundbeck Inc. Announces the Voluntary Nationwide Recall of Two Lots of NeoProfen® (ibuprofen lysine) Injection Recall will Result in Temporary Product Shortage

Lundbeck Inc. Announces the Voluntary Nationwide Recall of Two Lots of NeoProfen® (ibuprofen lysine) Injection Recall will Result in Temporary Product Shortage
Fri, 30 Jul 2010 22:58:00 -0500

– Lundbeck Inc. has voluntarily recalled two lots of NeoProfen® (ibuprofen lysine) Injection that failed to meet a visible particulate quality requirement. These two lots are the only lots currently available to prescribers and therefore the recall will result in a temporary drug shortage. This voluntary recall is the result of the company’s inspections of the two product lots of NeoProfen.

---

Manage your FDA Subscriptions:

• Update your preferences or unsubscribe
• Questions about this service? support@xxxxxxxxxxxxxxx
• Other inquiries? webmail@xxxxxxxxxx

GovDelivery, Inc. sending on behalf of U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · 10903 New Hampshire Ave MD 20993 · 800-439-1420